Amylyx Downgraded as PSP Program Ends, Avexitide Phase 3 Trial Beams Focus to Q3 2026 Inflection

What happened

Amylyx Pharmaceuticals was downgraded from 'Strong Buy' to 'Buy' after discontinuing its AMX0035 program for progressive supranuclear palsy (PSP), effectively narrowing its investment thesis to avexitide for post-bariatric hypoglycemia (PBH). The company's future now hinges on the pivotal Phase 3 LUCIDITY trial for avexitide, with topline data expected in Q3 2026, positioning this as a critical binary catalyst. While a new article touts a $317 million cash position funding into 2028, SEC filings reveal the company remains a loss-making, clinical-stage biotech with no product revenue and a history of late-stage failure with Relyvrio. The stock has surged over 200% in the past year to a $1.0 billion market cap, implying investors are pricing in significant success for avexitide despite high clinical and regulatory risks. This concentration amplifies vulnerabilities, as any setback in the LUCIDITY trial could severely impact valuation amid ongoing cash burn and competitive pressures in GLP-1 therapies.

Implication

The discontinuation of AMX0035 for PSP reduces pipeline diversification, making Amylyx's valuation almost entirely dependent on avexitide's success in the LUCIDITY trial, increasing overall risk exposure. Strong positive data could validate the current market cap and support potential commercialization, but failure would likely trigger a sharp sell-off given the lack of near-term alternatives. While the $317 million cash runway offers some financial buffer, persistent losses and the likelihood of future dilutive equity raises before commercialization pose ongoing threats to shareholder value. Historical missteps, including Relyvrio's withdrawal and significant workforce cuts, underscore execution and regulatory challenges that could compromise trial outcomes or market acceptance. For value-oriented investors, the negative intrinsic value and premium valuation provide limited margin of safety, reinforcing a cautious 'WAIT' stance until clearer clinical validation emerges.

Thesis delta

The investment thesis has shifted towards a more concentrated bet on avexitide, with the PSP program discontinuation eliminating a pipeline component and heightening reliance on the LUCIDITY trial outcome. This reinforces the master report's 'WAIT' judgment by increasing binary risk and reducing optionality, necessitating even stricter scrutiny of trial progress and financial discipline ahead of the Q3 2026 catalyst.